ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Social Drivers of Guideline-Discordant Breast Cancer Screening by Age and Mortality Risk.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUnderstanding social drivers of mammography screening is critical to implementing breast cancer screening guidelines that maximize benefits and minimize harms across diverse populations. We examined racial/ethnic, socioeconomic, and geographic patterns in guideline-discordant underscreening and overscreening according to guidelines based on age and mortality risk.
methodsWe used 2022 Behavioral Risk Factor Surveillance System data and major screening guidelines to define screening participation. Underscreening captured mammography in the past 2 years among women ages 50 to 74 years. Overscreening included any mammography beyond age 74 years or among women ages 50+ years with high mortality risk. We used modified Poisson regression to examine screening by race/ethnicity, regular healthcare provider access, and metropolitan, educational, and marital status.
resultsAmong 88,326 women ages 50 to 74 years, compared with non-Hispanic (NH) White, NH American Indian/Alaskan Native [adjusted prevalence ratio (aPR) = 0.88, 95% confidence interval (CI), 0.79-0.97] and NH women of unknown race (aPR = 0.86, 95% CI, 0.78-0.94) were less likely to be screened, whereas NH Black (aPR = 1.11, 95% CI, 1.09-1.13) women were more likely. Among 31,477 women ages 75+ years, NH Black women were more likely to be screened than NH White women (aPR = 1.07, 95% CI, 1.01-1.14). Among women with high mortality risk, NH Black (aPR = 1.20, 95% CI, 1.12-1.28) women were more likely to be screened than NH White women. Screening was lower among women with more limited socioeconomic resources regardless of age or mortality risk.
conclusionsFindings reveal social drivers of underscreening and overscreening and the need for equitable breast cancer screening delivery. IMPACT: This work calls for strengthening implementation and de-implementation efforts to optimize breast cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.